Stefano Sammicheli

Title: The Innovative Contributions of Stefano Sammicheli

Introduction

Stefano Sammicheli is a notable inventor based in La Chaux-de-Fonds, Switzerland. He has made significant contributions to the field of immunology through his innovative work on bispecific antibodies. His research focuses on developing novel therapeutic solutions for autoimmune and proliferative diseases, including various forms of cancer.

Latest Patents

Stefano Sammicheli holds a patent for CD47-CD38 bispecific antibodies. This patent describes a class of bispecific heterodimeric immunoglobulins that target both the human CD47 antigen and the human CD38 antigen. The invention specifically includes antibodies that comprise an anti-CD38 heavy chain variable region and a light chain variable region, as well as an anti-CD47 heavy chain variable region and a light chain variable region. The application of this novel class of antibodies is aimed at treating autoimmune diseases and cancers, particularly hematologic malignancies and solid tumors.

Career Highlights

Stefano Sammicheli is associated with Igi Therapeutics SA, where he continues to advance his research in immunotherapy. His work is pivotal in the development of new treatment modalities that could potentially improve patient outcomes in oncology and autoimmune disorders.

Collaborations

Stefano collaborates with talented professionals in his field, including Laure Bouchez and Blandine Pouleau. These collaborations enhance the research environment and contribute to the innovative solutions being developed at Igi Therapeutics SA.

Conclusion

Stefano Sammicheli's contributions to the field of immunology through his patent on bispecific antibodies represent a significant advancement in therapeutic options for challenging diseases. His ongoing work at Igi Therapeutics SA continues to pave the way for future innovations in cancer treatment and autoimmune disease management.